Abbott Laboratories

- No specific mention of new fundraising through debt or equity in the provided transcript. - Robert Ford highlights Abbott's strong balance sheet with at least $20 billion in firepower. - The company shows flexibility in capital allocation but emphasizes selective M&A based on strategic fit and attractive returns. - Abbott is not currently seeking acquisitions merely to boost top-line revenue. - Large deals need strong cash flow and ROIC justification, making them harder to do. - No indication given that Abbott plans to raise new equity or debt for financing at this time; focus remains on organic growth and disciplined capital deployment.

- Abbott is investing in line extensions for the Navitor product in the TAVI space, launching two new versions: Navitor Vision and Navitor Titan in 2024. - Continued investment in clinical trials and product development, including on Volt and biosimilars in the Emerging Pharmaceuticals Division (EPD). - Significant focus on pipeline and long-term growth opportunities, including the Fab 5 product portfolio and other initiatives to sustain growth beyond 2024 and 2025. - The company maintains a strong balance sheet with firepower of at least $20 billion, enabling selective and strategic M&A investments to complement organic growth. - Abbott emphasizes investing in technologies that improve patient outcomes and drive market growth, particularly in med tech and diagnostics, rather than merely boosting top-line figures.

- Abbott forecasts 8% to 10% organic sales growth in 2024, excluding COVID testing sales. - The "Fab 5" products are expected to contribute about 1 percentage point to overall growth in 2024 and continue growing around 50% year-over-year. - Nutrition segment projected to grow above the pre-pandemic mid-single-digit range (4%-6%), potentially breaking above 6% driven by the adult nutrition segment growing high single digits. - Medical devices and diagnostics show strong momentum with continuous double-digit growth in key business areas such as FreeStyle Libre and electrophysiology. - Pipeline investments across diagnostics, med tech, nutrition, and pharmaceuticals expected to sustain growth beyond 2024-2025. - Abbott maintains strong confidence in multi-year sustainable growth driven by product launches, market share gains, and new growth verticals in emerging markets.

- Abbott forecasts total underlying base business organic sales growth of 8% to 10% for 2024, excluding COVID testing sales. - Adjusted earnings per share (EPS) outlook is $4.50 to $4.70 for 2024, which includes Q1 EPS forecast of $0.93 to $0.97. - The company expects double-digit earnings-per-share growth at the midpoint for 2024. - Margin expansion is anticipated, with a focus on gross margin improvement projected to increase by roughly 75 basis points in 2024. - Profitability emphasis is on generating attractive returns on investments rather than just top-line growth via M&A. - Abbott forecasts adjusted tax rate of 15% for 2024 and reflects continued robust contributions from pipeline growth and the "Fab 5" product group, which will accelerate and contribute about a one-point growth to the overall company. - Operational spending has been managed strategically to maintain margins near pre-pandemic levels, with opportunities for further gross margin expansion.

The provided transcript does not mention specific details regarding Abbott Laboratories' current or expected order book or pending orders. The discussion primarily focuses on: - 2023 financial performance and growth outlook for 2024. - Strong organic sales growth across all major business segments. - Pipeline of new products and innovations contributing to future growth. - No disclosure or reference to order backlog, order book size, or pending orders status. Therefore, there is no information available in the transcript about the company's order book or pending orders.